APP and Alzheimer disease: Last but not least, our data support the use of GSEC-targeting molecules securing GSEC-APP/Aβn interactions, and consequently shifting Aβ profiles towards short and less amyloidogenic peptides, as promising therapeutics in FAD and broadly in AD.